FEATURED 2020 SPEAKERS

 

2020 SPEAKERS

 

Stewart Abbot, Chief Scientific Officer, Adicet Bio

Stewart Abbot | Chief Scientific Officer | Adicet Bio » speaking at Advanced Therapies

Hinrich Abken, Chair for Genetic Immunotherapy, University Hospital Regensburg

Elsa Abranches, Group Leader, Section Of Stem Cell Biology, NIBSC/MHRA

Prasad Adusumilli, Deputy Chief, Thoracic Surgery; Vice Chair, Dept. of Surgery,, Memorial Sloan-Kettering Cancer Center

Joachim Aerts, Head of the Department, Professor of Pulmonary Medicine, Pulmonary Diseases, Erasmus M.C.

Pinar Akcakaya, Senior Research Scientist, AstraZeneca

Pinar Akcakaya | Senior Research Scientist | AstraZeneca » speaking at Advanced Therapies

Mehrshid Alai-Safar, Head of CMC and Regulation, Kite Pharma, a Gilead Company

Eric Alton, Professor Of Gene Therapy And Respiratory Medicine, Faculty of Medicine National Heart and Lung Institute Imperial College London

Stephen Badylak, Deputy Director, Mcgowan Institute For Regenerative Medicine, University of Pittsburgh

Cynthia Bamdad, Chief Executive Officer, Minerva Biotechnologies Corp

Ricardo Baptista, Director Process & Analytical Development, Cellectis Therapeutics

Ricardo Baptista | Director Process & Analytical Development | Cellectis Therapeutics » speaking at Advanced Therapies

Frank Barry, Scientific Director, Regenerative Medicine Institute

Frank Barry | Scientific Director | Regenerative Medicine Institute » speaking at Advanced Therapies

Dr Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)

Elena Beltrami, Business Development Manager, Fondazione Telethon

Tim Bertram, Chief Executive Officer, inRegen

Tim Bertram | Chief Executive Officer | inRegen » speaking at Advanced Therapies

David Blakey, Chief Scientific Officer, Mina Therapeutics

Axel Boehnke, Director Market Access Eu North, PTC Therapeutics

Jaap Boelens, Chief; Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center

Luc Boileau, Chairman And Chief Executive Officer, INESSS

Luc Boileau | Chairman And Chief Executive Officer | INESSS » speaking at Advanced Therapies

Amandine Breton, Cell Therapy Operations Manager, Orchard Therapeutics

Todd C Mcdevitt, Senior Investigator, Gladstone Institute

Todd C Mcdevitt | Senior Investigator | Gladstone Institute » speaking at Advanced Therapies

Didier Caizergues, Director Of Regulatory Affairs, Genethon

John Campbell, Associate Director, Tissues, Cells And Advanced Therapeutics, Scottish National Blood Transfusion Service

Manuel Carrondo, Professor, iBET: Instituto de Biologia Experimental e Tecnológica

Paul S Carter, Cell And Gene Therapy Platform Cmc, GlaxoSmithKline

Paul S Carter | Cell And Gene Therapy Platform Cmc | GlaxoSmithKline » speaking at Advanced Therapies

Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics

Frederic Chereau | Chief Executive Officer | LogicBio Therapeutics » speaking at Advanced Therapies

Vittorio Colizzi, Professor Of Immunology, University of Rome Tor Vergata

Vittorio Colizzi | Professor Of Immunology | University of Rome Tor Vergata » speaking at Advanced Therapies

Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics

Randolph Corteling, Head of Research, ReNeuron Group Plc

Elena Costariol, Engd Researcher, UCL

Christina Coughlin, Chief Medical Officer, Tmunity Therapeutics

Chandler Crews, President, The Chandler Project, Inc

Conrad Russell Y Cruz, Translational Research Laboratories Director, Children's National Medical Center

Davide Danovi, Director, Hipsci Cell Phenotyping Programme, King's College London

Derek Dashti, Founder And Chief Executive Officer, D and P Bioinnovations

Derek Dashti | Founder And Chief Executive Officer | D and P Bioinnovations » speaking at Advanced Therapies

Eric Michael David, Chief Executive Officer, BridgeBio-Gene Therapy

Francesco Dazzi, Professor Of Regenerative And Hematological Medicine, King's College London

Francesco Dazzi | Professor Of Regenerative And Hematological Medicine | King's College London » speaking at Advanced Therapies

Joery De Kock, Professor, Vrije Universiteit Brussel

Joery De Kock | Professor | Vrije Universiteit Brussel » speaking at Advanced Therapies

Robert Deans, Chief Innovation Officer, BlueRock Therapeutics

Robert Deans | Chief Innovation Officer | BlueRock Therapeutics » speaking at Advanced Therapies

Chirag Desai, Professor of Surgery, Director, Chronic Pancreatitis & Autologous-Islet Cell Transplant Program, University Of North Carolina School Of Medicine

Joe Dupere, Chief Executive Officer, Rexgenero Ltd..

Kris Elverum, Senior Vice President Of Business Development And Strategy, Rubius Therapeutics

Kris Elverum | Senior Vice President Of Business Development And Strategy | Rubius Therapeutics » speaking at Advanced Therapies

Victoria English, Victoria English, Co-Founder And Editor, Evernow Publications

Debora Esposito, Phd Candidate, N.C. State University

Debora Esposito | Phd Candidate | N.C. State University » speaking at Advanced Therapies

Marco Fadda, Atmp And Regenerative Medicine Solutions Specialist, COMECER GROUP

Marco Fadda | Atmp And Regenerative Medicine Solutions Specialist | COMECER GROUP » speaking at Advanced Therapies

Dr Suzanne Farid, Biochemical Engineering Professor, University College London

Dr Suzanne Farid | Biochemical Engineering Professor | University College London » speaking at Advanced Therapies

Prof Farzin Farzaneh, Professor Of Molecular Medicine, King's College Hospital

Miguel Forte, Chief Executive Officer, Zelluna Immunotherapy

Miguel Forte | Chief Executive Officer | Zelluna Immunotherapy » speaking at Advanced Therapies

Hans-Juergen Fuelle, NIBR, Global Therapeutic Area Lead RA Early Development, Novartis

Hans-Juergen Fuelle | NIBR, Global Therapeutic Area Lead RA Early Development | Novartis » speaking at Advanced Therapies

Michela Gabaldo, Head of Alliance Management, Fondazione Telethon

Bobby Gaspar, Professor of Paediatrics & Immunology, UCL Great Ormond Street Institute of Child Health

Bobby Gaspar | Professor of Paediatrics & Immunology | UCL Great Ormond Street Institute of Child Health » speaking at Advanced Therapies

André Gerth, CEO, BioPlanta GmbH

Faruque Ghanchi, Consultant Ophthalmologist, Head, Bradford Ophthalmology Research Network (BORN), Specialty Lead- Ophthalmology,, Bradford Teaching Hospitals N.H.S. Foundation Trust

Faruque Ghanchi | Consultant Ophthalmologist, Head, Bradford Ophthalmology Research Network (BORN), Specialty Lead- Ophthalmology, | Bradford Teaching Hospitals N.H.S. Foundation Trust » speaking at Advanced Therapies

Dr David Gilham, Vice President Of Research And Development, Celyad

Janet Glassford, Quality Assessor, Medicines & Healthcare Products Regulatory Agency

Janet Glassford | Quality Assessor | Medicines & Healthcare Products Regulatory Agency » speaking at Advanced Therapies

Cecilia Götherström, Research Leader And Associate Professor, Karolinska Institute

Julian Gough, Chief Scientific Officer, Mogrify

Lise Marie Grav, Postdoc, Technical University of Denmark

Boris Greber, Chief Scientific Officer, RheinCell Therapeutics

David Greenwald, Vice President Of Business Development, Deerfield Management

Uta Griesenbach, Professor, Molecular Medicine, National Heart and Lung Institute; President, British Society for Gene and Cell Therapy;, Imperiai College London

Ravindra Gupta, Wellcome Trust Senior Fellow In Clinical Science, Ucl Division Of Infection And Immunity, UCL

Ravindra Gupta | Wellcome Trust Senior Fellow In Clinical Science, Ucl Division Of Infection And Immunity | UCL » speaking at Advanced Therapies

Miriam Haak, Business Development Manager, Miltenyi Biotec GmbH

Miriam Haak | Business Development Manager | Miltenyi Biotec GmbH » speaking at Advanced Therapies

Sam Hall, Partner, Apple Tree Partners

Sam Hall | Partner | Apple Tree Partners » speaking at Advanced Therapies

Patrick J Hanley, Director, Cellular Therapy Laboratory, Children's National Medical Center

Patrick J Hanley | Director, Cellular Therapy Laboratory | Children's National Medical Center » speaking at Advanced Therapies

Namir Hassan, Chief Scientific Officer, Zelluna Immunotherapy

Namir Hassan | Chief Scientific Officer | Zelluna Immunotherapy » speaking at Advanced Therapies

Hansjörg Hauser, Head Of Department Of Scientific Strategy, Helmholtz Centre for Infection Research GmbH

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

Christopher R. Heery, Chief Medical Officer, Precision Biosciences

Hilary Hehman, Strategic Partnerships And Alliances Director, Fred Hutchinson Cancer Research Center

Hilary Hehman | Strategic Partnerships And Alliances Director | Fred Hutchinson Cancer Research Center » speaking at Advanced Therapies

Dawn Henke, Senior Technical Program Manager, Standards Coordinating Body

Dawn Henke | Senior Technical Program Manager | Standards Coordinating Body » speaking at Advanced Therapies

Christoph Herwig, Professor Of Biochemical Engineering, Vienna University of Technology

Edward Hodgkin, Partner, Syncona Partners

Johnny Huard, Director and Chief Scientific Officer, Center for Regenerative Sports Medicine,, Steadman Philippon Research Institute

Annie Hubert, Director, European Public Policy, Alliance for Regenerative Medicine

Annie Hubert | Director, European Public Policy | Alliance for Regenerative Medicine » speaking at Advanced Therapies

Michael Hunt, Chief Finance Officer, ReNeuron Group Plc

Dr Moshe Israeli, Medical Director, Rabin Medical Center

Agnieszka Janeczek, Founder/COO, Renovos

Bjarki Johannesson, Senior Research Investigator, The New York Stem Cell Foundation

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

John Johnston | Clinical Assessor | Medicines & Healthcare Products Regulatory Agency » speaking at Advanced Therapies

Robert Jones, Vice President, Global Bioservices, Cryoport Inc

Troels Jordansen, Chief Executive Officer, Glycostem

Margareth Jorvid, Head Of Regulatory Affairs and QA, Immunicum

Margareth Jorvid | Head Of Regulatory Affairs and QA | Immunicum » speaking at Advanced Therapies

Vaidehi Joshi, Scientist II, Therapeutics,, Organovo

Dr Bo Kara, VP Process Development, Evox Therapeutics

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

Sven Kili, Vice President And Head Of Gene Therapy Development, Sven Kili Consulting

Sven Kili | Vice President And Head Of Gene Therapy Development | Sven Kili Consulting » speaking at Advanced Therapies

Soekjoong Kim, R&D Managing Director, ToolGen

Katja Kleinsteuber, Scientist II, Cellular Analytics, bluebird bio

Jarema (Jarko) Kochan, Head Of Biomarkers, Diagnostics And Assay Development, Turnstone Biologics

Shane Kovacs, Chief Business Officer And Chief Financial Officer, BlueRock Therapeutics

Shane Kovacs | Chief Business Officer And Chief Financial Officer | BlueRock Therapeutics » speaking at Advanced Therapies

Sebastian Kress, Post Doc, BOKU

Jurgen Kuball, Professor, UMC Utrecht

Jurgen Kuball | Professor | UMC Utrecht » speaking at Advanced Therapies

Dmitry Kuzmin, Managing Partner, 4Bio Capital

Lawrence Lamb, Executive Vice President And Chief Scientific Officer, Incysus Therapeutics

Christine Le Bec, Head Of Analytical Development, Genethon

Christine Le Bec | Head Of Analytical Development | Genethon » speaking at Advanced Therapies

Jane Lebkowski, President, Regenerative Patch Technologies

Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics Inc

Steven Lee, Senior Research Fellow, Institute of Immunology and Immunotherapy, University of Birmingham

Dave Lennon, President, AveXis

Douglas Losordo, Chief Medical Officer, Caladrius Biosciences

Douglas Losordo | Chief Medical Officer | Caladrius Biosciences » speaking at Advanced Therapies

Mark Lowdell, Chief Scientific Officer, Inmunebio

Mark Lowdell | Chief Scientific Officer | Inmunebio » speaking at Advanced Therapies

Tim Luker, Global Director, External Innovation, External Research & Development, Eli Lilly And Company

Tim Luker | Global Director, External Innovation, External Research & Development | Eli Lilly And Company » speaking at Advanced Therapies

Frank Luyten, Director, Katholeieke Universiteit Leuven

Dr Danilo Maddalo, Laboratory Head, Novartis Institutes for BioMedical Research

John Maher, Chief Scientific Officer, Leucid Bio

Dawn Maier, Sr. Director Process Development and Manufacturing, ElevateBio

Sakis Mantalaris, Professor, Biomedical Systems Engineering Laboratory, Georgia Institute of Technology

Giuseppe Mazza, Chief Executive And Scientific Officer, Engitix

Giuseppe Mazza | Chief Executive And Scientific Officer | Engitix » speaking at Advanced Therapies

David Mazzo, Chief Executive Officer, Caladrius Biosciences

Aisleen Mccoll-Carboni, Senior Scientist, Sanofi

Aisleen Mccoll-Carboni | Senior Scientist | Sanofi » speaking at Advanced Therapies

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

Joanna Miller | Chief Scientific Officer | Cell Therapy Sciences » speaking at Advanced Therapies

Federico Mingozzi, Chief Scientific Officer, Spark Therapeutics

Federico Mingozzi | Chief Scientific Officer | Spark Therapeutics » speaking at Advanced Therapies

Maria Mirotsou, Senior Director, Research, Astellas Pharma

Maria Mirotsou | Senior Director, Research | Astellas Pharma » speaking at Advanced Therapies

Jennifer Moody, Senior Director, Research Operations, BlueRock Therapeutics

Neill Moray Mackenzie, Chairman And Board Mamber, Immetacyte

Neill Moray Mackenzie | Chairman And Board Mamber | Immetacyte » speaking at Advanced Therapies

Dave C Morris, Vice President Of Therapeutic Discovery, Precision Biosciences

David Morrow, Program Manager, EATRIS

Mary Murphy, Principle Investigator, Remedi National University of Ireland Galway

Mary Murphy | Principle Investigator | Remedi National University of Ireland Galway » speaking at Advanced Therapies

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Susan Nichols, President and CEO, Falcon Therapeutics

Susan Nichols | President and CEO | Falcon Therapeutics » speaking at Advanced Therapies

Jelena Ochs, Manager Business Unit Life Sciences Engineering, Fraunhofer Institute for Production Technology

Daniel O'Mahony, Partner, Seroba Life Sciences

Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC

Nneka Onwudiwe | Founder And Chief Executive Officer | Pharmaceutical Economics Consultants of America (PECA) LLC » speaking at Advanced Therapies

Dominic O'Regan, Director And Investor, New Mosaic

Emanuele Ostuni, Head Of Europe, Cell And Gene Therapy, Novartis

Emanuele Ostuni | Head Of Europe, Cell And Gene Therapy | Novartis » speaking at Advanced Therapies

Palani Palaniappan, Head Of Technical Operations And Andover Site, Sarepta Therapeutics

Sean Palecek, Professor of Chemical and Biological Engineering, University of Wisconsin, Stem Cell and Regenerative Medicine Center

Ioannis Papantoniou, Adjunct Professor, KU Leuven

Detlev Parow, Head Pharmaceutical Department, D.A.K.

Leonard Pattenden, Head Of Biotherapeutics Development And Drug Supply Biotherapeutics Development Unit, Cancer Research UK

C. David Pauza, Chief Science Officer, American Gene Technologies International Inc.

Sergey Piletsky, Professor, University of Leicester

Sergey Piletsky | Professor | University of Leicester » speaking at Advanced Therapies

Roland Pochet, Professor, Universite Libre De Bruxelles

Carolyn Porter, Cbo, Oxstem

Carolyn Porter | Cbo | Oxstem » speaking at Advanced Therapies

Dr Qasim Rafiq, Associate Professor, Bioprocessing Of Cell And Gene Therapies, University College London

Abdulkader Rahmo, Chief Executive Officer, SMSbiotech

Lior Raviv, Vice President Of Development, Pluristem Therapeutics

Petra Reinke, Founding Director, BeCAT; Steering Committee BCRT, Charite

Albert Ribickas, Bmt/Qc Laboratories Manager, Cell Therapies Facility, Moffitt Cancer Center

Jim Richardson, Senior Science and Standards Liaison, U.S. Pharmacopeia

Jim Richardson | Senior Science and Standards Liaison | U.S. Pharmacopeia » speaking at Advanced Therapies

Erik Richardson, Senior Manager, Gene Therapy R&D, Apellis Pharmaceuticals

Erik Richardson | Senior Manager, Gene Therapy R&D | Apellis Pharmaceuticals » speaking at Advanced Therapies

Dr Barry Rosen, Senior Principal Scientist And Director, AstraZeneca

Delphine Roulland, Director Government Affairs And Public Policy, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Delphine Roulland | Director Government Affairs And Public Policy | European Confederation of Pharmaceutical Entrepreneurs (Belgium) » speaking at Advanced Therapies

Igor Rudychev, Head Of Us Digital, Data, And Innovations, AstraZeneca

Igor Rudychev | Head Of Us Digital, Data, And Innovations | AstraZeneca » speaking at Advanced Therapies

Hans S. Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc.

Mark Sawicki, Chief Commercial Officer, Cryoport Inc

David Schaffer, Professor, Chemical and Biomolecular Engineering, University of California, Berkeley, and Co-Founder,, 4D Molecular Therapeutics

Emmett Schmidt, Associate Vice President, Clinical Research, Oncology, Merck Research Laboratories

Emmett Schmidt | Associate Vice President, Clinical Research, Oncology | Merck Research Laboratories » speaking at Advanced Therapies

Dominic Schmidt, Partner, Syncona Investment Management Ltd

Jan Schrooten, Co-Founder & CEO, Antleron

Elizabeth Schwarzbach, Chief Business Officer, The New York Stem Cell Foundation

Margarida Serra, Head of Stem Cell Bioengineering Laboratory, iBET: Instituto de Biologia Experimental e Tecnológica

Ra Session II, Chief Business Officer, BridgeBio-Gene Therapy

Ra Session II | Chief Business Officer | BridgeBio-Gene Therapy » speaking at Advanced Therapies

Andrew Sewell, Professor, Infection And Immunity, Cardiff University

Andrew Sewell | Professor, Infection And Immunity | Cardiff University » speaking at Advanced Therapies

Ilya Shestopalov, Associate Director, Cell Analytics, bluebird bio

Yochi Slonim, Co-Founder And Chief Executive Officer, Anima Biotech

Owen Smith, Investment Director, 4Bio Capital

Owen Smith | Investment Director | 4Bio Capital » speaking at Advanced Therapies

Devyn Smith, Chief Operating Officer & Head of Strategy, Sigilon

Alan Smith, Executive Vice President, Technical Operations, Bellicum Pharmaceuticals

Eric Soller, Vice President Of Corporate Development And Strategy, BlueRock Therapeutics

Kate Strayer-Benton, Senior Director, Business Development, Dana Farber Cancer Institute

Kate Strayer-Benton | Senior Director, Business Development | Dana Farber Cancer Institute » speaking at Advanced Therapies

Fatima Sulaiman, Head Of Research And Services, Scleroderma and Raynaud's UK

Bill Tente, Chief Regulatory Officer, Humacyte

Bill Tente | Chief Regulatory Officer | Humacyte » speaking at Advanced Therapies

Lawrence Thompson, Senior Principal Scientist, Analytical Research and Development, Pfizer

Pascal Touchon, President, Chief Executive Officer And Board Member, Atara Biotherapeutics

Evelina Vågesjö, CEO, Ilya Pharma

Dr Bob Valamehr, Chief Development Officer, Fate Therapeutics

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

Edward Van Wezel, Managing Partner, Bgv Biogeneration Ventures

Dr Alain Vertes, Managing Director, NxR Biotechnologies

Wen Bo Wang, Senior Vice President Of Technical Operations, Fate Therapeutics

Wen Bo Wang | Senior Vice President Of Technical Operations | Fate Therapeutics » speaking at Advanced Therapies

Dr Michael West, Founder and CEO, AgeX Therapeutics

Adrian Woolfson, Executive Vice President, Research and Development, Sangamo Theraputics

Bo Yan, Senior Scientist, Analytical Development, Beam Therapeutics

Dr Masahide Yano, Research Scientist, U.S. Food and Drug Administration

Stefano Zancan, Head Clinical Development And Operations, Fondazione Telethon

 

 

 

 

“Let me congratulate you on a job well done in helping organise the speakers and presentations for last week's Advanced Therapies Congress. I thought the entire meeting had a lot of substance, which made it stand out from many other meetings.”

 

Editor, Evernow Publishing Ltd